The Novo Nordisk IT Security Incident has resulted in unauthorized access to a limited number of the pharmaceutical company's internal IT systems, leading to the exposure of certain non-public information, including personal data related to clinical trial participants and healthcare professionals. The Denmark-based healthcare company confirmed that an investigation is underway with support from external cybersecurity experts and relevant authorities.

According to Novo Nordisk, certain data was copied externally without authorization during the incident. In response, the company temporarily took some internal systems offline and is gradually restoring affected environments in a controlled ma...